Ausgabe 1/2019
Inhalt (26 Artikel)
Is sentinel node biopsy necessary in the radiologically negative axilla in breast cancer?
Felix Jozsa, Muneer Ahmed, Rose Baker, Michael Douek
Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis
Bei Dong, Congyan Xie, Xiuchen Jing, Lu Lin, Li Tian
Prognostic role of immune infiltrates in breast ductal carcinoma in situ
Xiao-Yang Chen, Joe Yeong, Aye Aye Thike, Boon Huat Bay, Puay Hoon Tan
Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists
Erik Hedrick, Xi Li, Yating Cheng, Alexandra Lacey, Kumaravel Mohankumar, Mahsa Zarei, Stephen Safe
Breast cancer outcome prediction with tumour tissue images and machine learning
Riku Turkki, Dmitrii Byckhov, Mikael Lundin, Jorma Isola, Stig Nordling, Panu E. Kovanen, Clare Verrill, Karl von Smitten, Heikki Joensuu, Johan Lundin, Nina Linder
Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study
Marta Pineda-Moncusí, Sonia Servitja, Ignasi Tusquets, Adolfo Diez-Perez, Albora Rial, Maria Lourdes Cos, Isabel Campodarve, Jaime Rodriguez-Morera, Natalia Garcia-Giralt, Xavier Nogués
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
Melissa Krystel-Whittemore, Jin Xu, Edi Brogi, Katia Ventura, Sujata Patil, Dara S. Ross, Chau Dang, Mark Robson, Larry Norton, Monica Morrow, Hannah Y. Wen
The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay
C. Elfgen, Z. Varga, K. Reeve, L. Moskovszky, V. Bjelic-Radisic, C. Tausch, U. Güth
Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome
Cody Plasterer, Shirng-Wern Tsaih, Amy R. Peck, Inna Chervoneva, Caitlin O’Meara, Yunguang Sun, Angela Lemke, Dana Murphy, Jennifer Smith, Sophia Ran, Albert J. Kovatich, Jeffrey A. Hooke, Craig D. Shriver, Hai Hu, Edith P. Mitchell, Carmen Bergom, Amit Joshi, Paul Auer, Jeremy Prokop, Hallgeir Rui, Michael J. Flister
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT)
Bassam Basulaiman, Arif Ali Awan, Dean Fergusson, Lisa Vandermeer, Angel Arnaout, John Hilton, Brian Hutton, Anil Abraham Joy, Andrew Robinson, Nadia Califaretti, Carol Stober, Marta Sienkiewicz, Kednapa Thavorn, Mark Clemons
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial
Matteo Lambertini, Christine Campbell, Richard D. Gelber, Giuseppe Viale, Ann McCullough, Florentine Hilbers, Larissa A. Korde, Olena Werner, Saranya Chumsri, Christian Jackisch, Antonio C. Wolff, Ines Vaz-Luis, Arlindo R. Ferreira, Aleix Prat, Alvaro Moreno-Aspitia, Martine Piccart, Sherene Loi, Evandro de Azambuja
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Manuel Ruíz-Borrego, Angel Guerrero-Zotano, Begoña Bermejo, Manuel Ramos, Josefina Cruz, Jose Manuel Baena-Cañada, Beatriz Cirauqui, Álvaro Rodríguez-Lescure, Emilio Alba, Noelia Martínez-Jáñez, Montserrat Muñoz, Silvia Antolín, Isabel Álvarez, Sonia Del Barco, Elena Sevillano, José Ignacio Chacón, Antonio Antón, María José Escudero, Victoria Ruiz, Eva Carrasco, Miguel Martín, M. A. Seguí, F. Ayala, J. de la Haba, P. Martínez, S. González, A. Lahuerta, J. C. Toral, E. Martínez de Dueñas, J. Florián, M. J. Godes, C. Llorca, I. Blancas, C. Jara, S. Morales, A. Arcusa, A. Martínez, E. Vicente, A. de Juan, M. Rodríguez, M. García, P. García, J. L. Bayo, V. Carañana, J. Casinello, L. Jolis, M. Gil, C. Cañabate, A. Oltra, J. Ramírez, M. Lomas, A. Barnadas, M. Sureda, F. Carabantes, I. Moreno, A. L. Moreno
Sharing in care: engaging care partners in the care and communication of breast cancer patients
Jennifer L. Wolff, Jennifer Aufill, Diane Echavarria, JaAlah-Ai Heughan, Kimberley T. Lee, Roisin M. Connolly, John H. Fetting, Danijela Jelovac, Katie Papathakis, Carol Riley, Vered Stearns, Elissa Thorner, Nelli Zafman, Howard P. Levy, Sydney M. Dy, Antonio C. Wolff
Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
Maria K. Pomponio, Luke J. Keele, Kevin R. Fox, Amy S. Clark, Jennifer M. Matro, Lawrence N. Shulman, Julia C. Tchou
Assessment of PARP4 as a candidate breast cancer susceptibility gene
Aldo Prawira, Prabhakaran Munusamy, Jimin Yuan, Claire Hian Tzer Chan, Geok Ling Koh, Timothy Wai Ho Shuen, Jiancheng Hu, Yoon Sim Yap, Min Han Tan, Peter Ang, Ann Siew Gek Lee
The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis
Helen M. Johnson, William Irish, Nasreen A. Vohra, Jan H. Wong
Combined effect of volumetric breast density and body mass index on breast cancer risk
Natalie J. Engmann, Christopher G. Scott, Matthew R. Jensen, Stacey Winham, Diana L. Miglioretti, Lin Ma, Kathleen Brandt, Amir Mahmoudzadeh, Dana H. Whaley, Carrie Hruska, Fang Wu, Aaron D. Norman, Robert A. Hiatt, John Heine, John Shepherd, V. Shane Pankratz, Celine M. Vachon, Karla Kerlikowske
The use of contralateral prophylactic mastectomy among elderly patients in the United States
Schelomo Marmor, Ariella M. Altman, William T. Mayleben, Jane Y. C. Hui, Jason W. Denbo, Eric H. Jensen, Todd M. Tuttle
Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database
Thomas Helland, Kari Britt Hagen, Martha Eimstad Haugstøyl, Jan Terje Kvaløy, Siri Lunde, Kirsten Lode, Ragna Anne Lind, Birgitta Haga Gripsrud, Kristin Jonsdottir, Jennifer Gjerde, Ersilia Bifulco, Steinar Hustad, Janne Jonassen, Turid Aas, Tone Hoel Lende, Ernst Asbjørn Lien, Emiel Adrianus Maria Janssen, Håvard Søiland, Gunnar Mellgren
Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice
Stephanie Saw, John Lim, Swee Ho Lim, Mabel Wong, Cindy Lim, Yoon Sim Yap
Employment trends in young women following a breast cancer diagnosis
Shoshana M. Rosenberg, Ines Vaz-Luis, Jingyi Gong, Padma Sheila Rajagopal, Kathryn J. Ruddy, Rulla M. Tamimi, Lidia Schapira, Steven Come, Virginia Borges, Janet S. de Moor, Ann H. Partridge
Is immediate breast reconstruction safe in women over 70? An analysis of the National Surgical Quality Improvement Program (NSQIP) database
Fernando A. Angarita, Fahima Dossa, Jesse Zuckerman, David R. McCready, Tulin D. Cil
Radiation oncology crossword: breast cancer
Shearwood McClelland III, Ryan M. Rhome, Richard C. Zellars
What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
Roberta Maltoni, Sara Bravaccini
Correction to: Racial disparities in surveillance mammography among older breast cancer survivors
Jimmitti Teysir, Nana Gegechkori, Juan P. Wisnivesky, Jenny J. Lin